[Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan].
Sada
Akiko
A
Matsui
Toshimitsu
T
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002908:Chronic Disease; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha; D011993:Recombinant Fusion Proteins; D012015:Reference Standards; D039221:mRNA Cleavage and Polyadenylation Factors
D000970:Antineoplastic Agents; D001549:Benzamides; C479818:FIP1L1 protein, human; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha